遠大醫藥(00512.HK)：聯營公司為豐富集團高創新性和高壁壘性產品管線近期達成相關交易及合作
格隆匯 12 月 9日丨遠大醫藥(00512.HK)發佈公告，集團的聯營公司Sirtex Medical US Holding, Inc (“Sirtex”)為豐富集團高創新性和高壁壘性產品管線，近期達成以下交易及合作:
1)Sirtex與Nanospectra Biosciences, Inc. (“Nanospectra”)達成如下交易：簽訂戰略投資協議(“Nanospectra協議”)，據此，Sirtex牽頭對Nanospectra進行了股權投資，以約150萬美元認購Nanospectra首輪約6%的B-1類優先股及有權任命一名董事會成員。同時雙方亦約定，Sirtex在一定期限內獲得Nanospectra在精準抗腫瘤介入領域中用於實體腫瘤消融的全球創新醫療器械產品AuroLase®在歐洲及亞洲地區的相關授權的獨家優先談判權，以及未來當Nanospectra擬轉讓控股權時享有獨家優先談判權。
該創新科技最初由美國科學院(National Academy of Sciences)及美國工程院(National Academy of Engineering)兩院院士Naomi Halas教授以及美國工程院院士Jennifer West教授共同帶領的科學家團隊負責開發，已於今年第一季度啟動前列腺組織消融的關鍵試驗。若該產品獲批，有望成為以超精準局灶療法治療局部前列腺癌領域中最早上市的全球創新產品。
Naomi Halas教授為萊斯大學(Rice University) 納米光子學實驗室的創始主任及 Smalley-Curl Institute所長，Naomi Halas教授作為等離子體技術領域的先驅研究人員之一，Naomi Halas 教授創造了“可調等離子體激元”的概念，一系列發明被廣泛應用於生物醫學、光電、化學傳感、光催化以及太陽能等多個領域。Naomi Halas教授與Jennifer West 教授共同創立Nanospectra以推進使用納米粒子對軟組織進行定向光熱治療的臨牀開發。
2)Sirtex 與 BlackSwan Vascular, Inc. (“BlackSwan”)達成如下交易：簽訂股份收購協議，據此，Sirtex將以約500萬美元收購BlackSwan約12.5%的股本權益，並可以選擇以約定價格購買公司剩餘股份。此外，Sirtex亦有權任命一位董事會觀察員。
BlackSwan核心產品LavaTM為一款精準血管介入領域的全球創新的醫療器械，於2020年9月獲得美國食品藥品管理局(“FDA”)的臨牀試驗器械豁免(“IDE”)批准開展臨牀試驗。LavaTM有望成為首個在美國獲得批准的外周血管液體栓塞劑。LavaTM在成像射線下具有不透明性，不易出現偽影同時可快速製備，製備過程只需3分鐘，操作便捷，在緊急狀況下為醫生節省準備時間提高患者生存概率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
